Bivalirudin and thrombolytic therapy: a novel successful treatment of severe aortic arch thrombosis in a term neonate.
An early-term infant with uncomplicated perinatal history was found to have a large thrombus in the aortic arch after he failed regular newborn critical congenital heart defect screen. He responded well to bivalirudin thrombolytic and tissue-plasminogen activator (tPA) combination therapy, with a significant resolution of the thrombus. The infant tolerated hospital admission well with no significant complications. He was discharged home on daily aspirin at 2 weeks of life. To our knowledge, the combination therapy approach with bivalirudin and tPA is the first one reported in the literature in the neonatal age group.
BMJ Case Rep
cardiovascular system; haematology (drugs and medicines); neonatal intensive care; paediatrics (drugs and medicines); routine care of the full-time infant
Taha A, Rajgarhia A, Alsaleem M. Bivalirudin and thrombolytic therapy: a novel successful treatment of severe aortic arch thrombosis in a term neonate. BMJ Case Rep. 2021;14(1):e239535. Published 2021 Jan 18. doi:10.1136/bcr-2020-239535